Comprehensive Medical Management of Peripheral Arterial Disease

Progress in Cardiovascular Diseases

Volumn 54, Issue 1, 2011, Pages 2-13

  Gandhi, Sanjay ^a   Weinberg, Ido ^a   Margey, Ronan ^a   Jaff, Michael R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Medical therapy; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIVITAMIN K; ARGININE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBROBLAST GROWTH FACTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL NICOTINATE; MESOGLYCAN; NAFTIDROFURYL; NICOTINE; PENTOXIFYLLINE; PERINDOPRIL; PLACEBO; PROSTANOID; RAMIPRIL; RIFALAZIL; SARPOGRELATE; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNINDEXED DRUG; VASCULOTROPIN; WARFARIN;

ADJUVANT THERAPY; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BEHAVIOR MODIFICATION; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIMB AMPUTATION; LIMB ISCHEMIA; METABOLIC SYNDROME X; MORTALITY; NEUTROPENIA; NICOTINE REPLACEMENT THERAPY; OBESITY; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK REDUCTION; SMOKING CESSATION; STROKE; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIET; EXERCISE THERAPY; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 79959750878     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.02.004     Document Type: Article

References (110)

1. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5-S67.
2. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-e654.
3. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324.
4. Diehm C., Allenberg J.R., Pittrow D., et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009, 120:2053-2061.
5. Zeymer U., Parhofer K.G., Pittrow D., et al. Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol 2009, 98:249-256.
6. Welten G.M., Schouten O., Hoeks S.E., et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008, 51:1588-1596.
7. Marso S.P., Hiatt W.R. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006, 47:921-929.
8. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743.
9. Wattanakit K., Folsom A.R., Selvin E., et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005, 180:389-397.
10. Kannel W.B., McGee D.L. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985, 33:13-18.
11. Mackaay A.J., Beks P.J., Dur A.H., et al. The distribution of peripheral vascular disease in a Dutch Caucasian population: comparison of type II diabetic and non-diabetic subjects. Eur J Vasc Endovasc Surg 1995, 9:170-175.
12. Dosluoglu H.H., Lall P., Nader N.D., et al. Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia. J Vasc Surg 2010, 51:1178-1189. [discussion 1188-1189].
13. Jude E.B., Oyibo S.O., Chalmers N., et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001, 24:1433-1437.
14. Bild D.E., Selby J.V., Sinnock P., et al. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989, 12:24-31.
15. DeRubertis B.G., Pierce M., Ryer E.J., et al. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg 2008, 47:101-108.
16. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
17. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
19. Patel A., MacMahon S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
20. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
21. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
22. Carter R.E., Lackland D.T., Cleary P.A., et al. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care 2007, 30:2646-2648.
23. American Diabetes Association Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61.
24. Olin J.W., Allie D.E., Belkin M., et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Circulation 2010, 122:2583-2618.
25. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007, 45:645-654. Heart Protection Study Collaborative Group, [discussion 653-654].
26. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
27. McDermott M.M., Guralnik J.M., Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003, 107:757-761.
28. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108:1481-1486.
29. Pedersen T.R., Kjekshus J., Pyorala K., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998, 81:333-335.
30. Beckman J.A., Creager M.A. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 2006, 16:156-162.
31. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
32. Willigendael E.M., Teijink J.A., Bartelink M.L., et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004, 40:1158-1165.
33. Price J.F., Mowbray P.I., Lee A.J., et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999, 20:344-353.
34. He Y., Lam T.H., Jiang B., et al. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation 2008, 118:1535-1540.
35. Faulkner K.W., House A.K., Castleden W.M. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983, 1:217-219.
36. Jonason T., Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987, 221:253-260.
37. Lip G.Y., Makin A.J. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2003, CD003075.
38. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
39. Singer D.R., Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?. Eur J Vasc Endovasc Surg 2008, 35:701-708.
40. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
41. Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
42. Radack K., Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991, 151:1769-1776.
43. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
44. Berger J.S., Krantz M.J., Kittelson J.M., et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009, 301:1909-1919.
45. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
46. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2141.
47. Fowkes F.G., Price J.F., Stewart M.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010, 303:841-848.
48. Dorffler-Melly J., Koopman M.M., Adam D.J., et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003, CD000535.
49. Vivas D., Angiolillo D.J. Platelet P2Y receptor inhibition: an update on clinical drug development. Am J Cardiovasc Drugs 2010, 10:217-226.
50. Zakarija A., Kwaan H.C., Moake J.L., et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009, S20-S24.
51. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
52. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
53. Belch J.J., Dormandy J., CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825,33, 833.e1-e2.
54. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
55. Morrow D.A., Wiviott S.D., White H.D., et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009, 119:2758-2764.
56. Anand S., Yusuf S., et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators: Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007, 357:217-227.
57. Murphy T.P., Hirsch A.T., Ricotta J.J., et al. The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods. J Vasc Surg 2008, 47:1356-1363.
58. McDermott M.M., Greenland P., Liu K., et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002, 136:873-883.
59. McDermott M.M., Liu K., Greenland P., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004, 292:453-461.
60. McDermott M.M., Guralnik J.M., Tian L., et al. Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease. J Am Coll Cardiol 2007, 50:974-982.
61. Bendermacher B.L., Willigendael E.M., Nicolai S.P., et al. Supervised exercise therapy for intermittent claudication in a community-based setting is as effective as clinic-based. J Vasc Surg 2007, 45:1192-1196.
62. McDermott M.M., Ades P., Guralnik J.M., et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009, 301:165-174.
63. Spronk S., Bosch J.L., den Hoed P.T., et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 2008, 48:1472-1480.
64. Gardner A.W., Poehlman E.T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995, 274:975-980.
65. Mora S., Cook N., Buring J.E., et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007, 116:2110-2118.
66. Thompson P.D., Franklin B.A., Balady G.J., et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007, 115:2358-2368.
67. van Kuijk J.P., Flu W.J., Chonchol M., et al. Metabolic syndrome is an independent predictor of cardiovascular events in high-risk patients with occlusive and aneurysmatic peripheral arterial disease. Atherosclerosis 2010, 210:596-601.
68. Giugliano G., Brevetti G., Laurenzano E., et al. The prognostic impact of general and abdominal obesity in peripheral arterial disease. Int J Obes (Lond) 2010, 34:280-286.
69. Karason K., Peltonen M., Lindroos A.K., et al. Effort-related calf pain in the obese and long-term changes after surgical obesity treatment. Obes Res 2005, 13:137-145.
70. Giles K.A., Hamdan A.D., Pomposelli F.B., et al. Body mass index: surgical site infections and mortality after lower extremity bypass from the National Surgical Quality Improvement Program 2005-2007. Ann Vasc Surg 2010, 24:48-56.
71. Chapman T.M., Goa K.L. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003, 3:117-138.
72. Elam M.B., Heckman J., Crouse J.R., et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998, 18:1942-1947.
73. Otsuki M., Saito H., Xu X., et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis 2001, 158:121-128.
74. Hsieh C.J., Wang P.W. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009, 73:948-954.
75. Soga Y., Yokoi H., Kawasaki T., et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009, 53:48-53.
76. Pande R.L., Hiatt W.R., Zhang P., et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010, 15:181-188.
77. Thompson P.D., Zimet R., Forbes W.P., et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002, 90:1314-1319.
78. Robless P., Mikhailidis D.P., Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008, CD003748.
79. Hiatt W.R., Money S.R., Brass E.P. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008, 47:330-336.
80. Dawson D.L., Cutler B.S., Hiatt W.R., et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000, 109:523-530.
81. Boccalon H., Lehert P., Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris) 2001, 50:175-182.
82. Kieffer E., Bahnini A., Mouren X., et al. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001, 20:58-65.
83. Leng G. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in patients with peripheral arterial disease http://guidance.nice.org.uk/TA/Wave22/8.
84. Marchesi S., Pasqualini L., Lombardini R., et al. Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol 2003, 41:249-253.
85. Ruffolo A.J., Romano M., Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010, CD006544.
86. Pittler M.H., Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000, 108:276-281.
87. Nicolai S.P., Kruidenier L.M., Bendermacher B.L., et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009, CD006888.
88. Wilson A.M., Harada R., Nair N., et al. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007, 116:188-195.
89. Sommerfield T., Price J., Hiatt W.R. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007, CD003833.
90. de Backer T.L., Bogaert M., Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev 2008, CD000988.
91. Norgren L., Jawien A., Matyas L., et al. Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med 2006, 11:75-83.
92. Arosio E., De Marchi S., Zannoni M., et al. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2002, 77:754-759.
93. Nenci G.G., Gresele P., Ferrari G., et al. Treatment of intermittent claudication with mesoglycan-a placebo-controlled, double-blind study. Thromb Haemost 2001, 86:1181-1187.
94. Reiter M., Bucek R.A., Stumpflen A., et al. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004, CD000986.
95. Mohler E.R., Hiatt W.R., Olin J.W., et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003, 41:1679-1686.
96. van Rij A.M., Solomon C., Packer S.G., et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994, 90:1194-1199.
97. Kleijnen J., Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000, CD000987.
98. Sesso H.D., Buring J.E., Christen W.G., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008, 300:2123-2133.
99. Jaff M.R., Dale R.A., Creager M.A., et al. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 2009, 119:452-458.
100. Sneider E.B., Nowicki P.T., Messina L.M. Regenerative medicine in the treatment of peripheral arterial disease. J Cell Biochem 2009, 108:753-761.
101. Gupta R., Tongers J., Losordo D.W. Human studies of angiogenic gene therapy. Circ Res 2009, 105:724-736.
102. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
103. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
104. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
105. Rajagopalan S., Mohler E.R., Lederman R.J., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
106. Nikol S., Baumgartner I., Van Belle E., et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008, 16:972-978.
107. Hiatt WR: TAMARIS phase III NV 1 FGF gene therapy on amputation-free survival in critical limb ischemia-phase III randomized double-blind placebo controlled trial. Clinical trial presented at Scientific Sessions of the American Heart Association Nov 14-17, 2010, in Chicago.
108. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
109. Huang P.P., Li S.Z., Han M.Z., et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost 2004, 91:606-609.
110. Huang P., Li S., Han M., et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005, 28:2155-2160.